{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T05:06:02Z","timestamp":1696914362780},"reference-count":37,"publisher":"Wiley","issue":"s2","license":[{"start":{"date-parts":[[2002,1,4]],"date-time":"2002-01-04T00:00:00Z","timestamp":1010102400000},"content-version":"vor","delay-in-days":613,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Gastro and Hepatol"],"published-print":{"date-parts":[[2000,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This paper addresses two difficult issues in the treatment of hepatitis C: patients who fail to achieve a sustained response after the first course of treatment, and those who simultaneously suffer from chronic renal failure. With the recent improvements in firstline treatment, retreatment is mainly applicable to those who have previously received 6\u2010month of interferon monotherapy at 3 MU thrice weekly. For those who had an end\u2010of\u2010treatment response but relapsed, there is a choice between interferon monotherapy at increased dose and\/or duration of treatment, or a 6\u2010month course of combination therapy. Retreatment of non\u2010responders is generally unsuccessful, but some patients may respond to interferon\u2010alpha 3 MU and ribavirin 1.0\u20131.2 g\/day. For patients with chronic renal failure and hepatitis C, combination treatment is not possible because ribavirin is contraindicated. Interferon given at a dose of 1.5 MU thrice weekly was reported to be fairly well tolerated by patients who were on dialysis and resulted in end\u2010of\u2010treatment and sustained biochemical and virological response in some cases. Interferon given in the usual doses may be associated with severe adverse effects in patients with renal failure, and can precipitate allograft rejection in patients who have undergone renal transplantation.<\/jats:p>","DOI":"10.1046\/j.1440-1746.2000.02113.x","type":"journal-article","created":{"date-parts":[[2003,3,12]],"date-time":"2003-03-12T05:16:42Z","timestamp":1047446202000},"update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Hepatitis C: Retreatment and treatment of patients with renal failure"],"prefix":"10.1111","volume":"15","author":[{"given":"Wan\u2010Cheng","family":"Chow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,1,4]]},"reference":[{"key":"e_1_2_3_2_2","doi-asserted-by":"crossref","unstructured":"The National Institutes of Health Consensus Development Conference.Management of hepatitis C.Hepatology1997;26(Suppl. 1).","DOI":"10.1002\/hep.510260701"},{"key":"e_1_2_3_3_2","first-page":"387","article-title":"A study on the epidemiology of hepatitis C infection among blood donors in Singapore.","volume":"17","author":"Wan JE.","year":"1995","journal-title":"J. Public Health Med."},{"key":"e_1_2_3_4_2","first-page":"105","volume-title":"Selected Papers from the International Symposia on Viral Hepatitis and Hepatocelluar Carcinoma Research.","author":"Choong HL.","year":"1992"},{"issue":"1","key":"e_1_2_3_5_2","first-page":"S424","article-title":"Hepatitis C antibodies in patients on peritoneal dialysis: Prevalence and risk factors.","volume":"16","author":"Lee GSL","year":"1996","journal-title":"Perit. Dial. Int."},{"key":"e_1_2_3_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199111000-00010"},{"key":"e_1_2_3_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199204000-00011"},{"key":"e_1_2_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0272-6386(95)90617-7"},{"key":"e_1_2_3_9_2","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1097\/00007890-199510000-00007","article-title":"The impact of pre\u2010transplantation hepatitis C infection on the outcome of renal transplantation.","volume":"60","author":"Pereira BJG","year":"1995","journal-title":"Transplantation"},{"key":"e_1_2_3_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510270432"},{"key":"e_1_2_3_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811193392101"},{"key":"e_1_2_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07124-4"},{"key":"e_1_2_3_13_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1996.v111.pm8898645"},{"key":"e_1_2_3_14_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1997.v113.pm9352869"},{"key":"e_1_2_3_15_2","first-page":"1523","article-title":"Alpha\u2010interferon retreatment of patients with chronic hepatitis C.","volume":"91","author":"Rabinovitz M","year":"1996","journal-title":"Am. J. Gastrenterol."},{"issue":"12","key":"e_1_2_3_16_2","first-page":"S31","article-title":"Interferon\u2013 ribavirin combination therapy for chronic hepatitis C.","volume":"41","author":"Schalm SW","year":"1996","journal-title":"Dig. Dis. Sci."},{"key":"e_1_2_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(97)80103-1"},{"key":"e_1_2_3_18_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1999.0029900408"},{"key":"e_1_2_3_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2893.1999.00005.x"},{"key":"e_1_2_3_20_2","first-page":"286A","article-title":"High rate of complete response to combination therapy in patients with chronic hepatitis C (CHC) refractory to interferon alfa.","volume":"28","author":"Pinar A","year":"1998","journal-title":"Hepatology"},{"key":"e_1_2_3_21_2","first-page":"245","article-title":"Interferon and ribavirin for the treatment of relapse and non\u2010responders of chronic hepatitis C.","volume":"30","author":"Kallinowski B","year":"1999","journal-title":"J. Hepatol."},{"key":"e_1_2_3_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510300113"},{"key":"e_1_2_3_23_2","first-page":"247","article-title":"Amantidine and interferon treatment of chronic \u2018non\u2010responders\u2019 HCV infected patients.","volume":"30","author":"Pompei A","year":"1999","journal-title":"J. Hepatol."},{"key":"e_1_2_3_24_2","first-page":"A1002","article-title":"Retreatment of hepatitis C interferon non\u2010responders with larger doses of interferon with and without phlebotomy.","volume":"106","author":"Van Thiel DH","year":"1994","journal-title":"Gastroenterology"},{"key":"e_1_2_3_25_2","first-page":"A1234","article-title":"High dose interferon with ribavirin or iron reduction for interferon\u2010resistant chronic hepatitis C.","volume":"116","author":"Kugelmas M","year":"1999","journal-title":"Gastroenterology"},{"key":"e_1_2_3_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510270431"},{"key":"e_1_2_3_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510300202"},{"key":"e_1_2_3_28_2","first-page":"A720","article-title":"Sustained responders to retreatment with consensus interferon (CIFN) have similar patterns of HCVRNA decrease regardless of genotype.","volume":"116","author":"Fromm H","year":"1999","journal-title":"Gastroenterology"},{"key":"e_1_2_3_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811193392102"},{"key":"e_1_2_3_30_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2893.1997.00142.x"},{"key":"e_1_2_3_31_2","doi-asserted-by":"crossref","unstructured":"Making sense of hepatitis C.Lancet1998;352:1485(Editorial).","DOI":"10.1016\/S0140-6736(98)00056-7"},{"key":"e_1_2_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)61494-8"},{"key":"e_1_2_3_33_2","first-page":"A49","article-title":"Retreatment of non\u2010responding chronic hepatitis C genotype 1 with a dose\u2010intensive course of combination therapy is cost\u2010effective.","volume":"116","author":"Carmona I","year":"1999","journal-title":"Gastroenterology"},{"key":"e_1_2_3_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(96)00101-7"},{"key":"e_1_2_3_35_2","doi-asserted-by":"publisher","DOI":"10.1159\/000189444"},{"key":"e_1_2_3_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/0272-6386(95)90623-1"},{"key":"e_1_2_3_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1994.197"},{"key":"e_1_2_3_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.1997.tb00213.x"}],"container-title":["Journal of Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1440-1746.2000.02113.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1046\/j.1440-1746.2000.02113.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T12:59:45Z","timestamp":1695733185000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1440-1746.2000.02113.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,5]]},"references-count":37,"journal-issue":{"issue":"s2","published-print":{"date-parts":[[2000,5]]}},"alternative-id":["10.1046\/j.1440-1746.2000.02113.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1440-1746.2000.02113.x","archive":["Portico"],"relation":{},"ISSN":["0815-9319","1440-1746"],"issn-type":[{"value":"0815-9319","type":"print"},{"value":"1440-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,5]]},"assertion":[{"value":"2002-01-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}